JP2025506821A5 - - Google Patents

Info

Publication number
JP2025506821A5
JP2025506821A5 JP2024550241A JP2024550241A JP2025506821A5 JP 2025506821 A5 JP2025506821 A5 JP 2025506821A5 JP 2024550241 A JP2024550241 A JP 2024550241A JP 2024550241 A JP2024550241 A JP 2024550241A JP 2025506821 A5 JP2025506821 A5 JP 2025506821A5
Authority
JP
Japan
Prior art keywords
composition according
receptor
glp
agonists
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506821A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2023/050192 external-priority patent/WO2023161934A1/en
Publication of JP2025506821A publication Critical patent/JP2025506821A/ja
Publication of JP2025506821A5 publication Critical patent/JP2025506821A5/ja
Pending legal-status Critical Current

Links

JP2024550241A 2022-02-24 2023-02-23 活性薬剤の経口投与用の酸中和ポリマーを含む製剤 Pending JP2025506821A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263313363P 2022-02-24 2022-02-24
US63/313,363 2022-02-24
PCT/IL2023/050192 WO2023161934A1 (en) 2022-02-24 2023-02-23 Formulations comprising acid-neutralizing polymer for oral administration of active agents

Publications (2)

Publication Number Publication Date
JP2025506821A JP2025506821A (ja) 2025-03-13
JP2025506821A5 true JP2025506821A5 (cg-RX-API-DMAC7.html) 2026-01-07

Family

ID=87765060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550241A Pending JP2025506821A (ja) 2022-02-24 2023-02-23 活性薬剤の経口投与用の酸中和ポリマーを含む製剤

Country Status (10)

Country Link
US (1) US20250186558A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482507A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506821A (cg-RX-API-DMAC7.html)
KR (1) KR20240152915A (cg-RX-API-DMAC7.html)
CN (1) CN119053335A (cg-RX-API-DMAC7.html)
AU (1) AU2023226618A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251862A1 (cg-RX-API-DMAC7.html)
IL (1) IL315198A (cg-RX-API-DMAC7.html)
MX (1) MX2024010387A (cg-RX-API-DMAC7.html)
WO (1) WO2023161934A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025046589A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5175553B2 (ja) * 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
WO2008070543A1 (en) * 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
WO2016128972A1 (en) * 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
MX2019001850A (es) * 2016-08-17 2019-05-15 Entera Bio Ltd Formulaciones para administracion oral de principios activos.
WO2018121702A1 (zh) * 2016-12-30 2018-07-05 江苏恒瑞医药股份有限公司 一种glp-1类似物的药物组合物及其制备方法
CN112587496A (zh) * 2020-12-16 2021-04-02 江苏海洋大学 一种艾塞那肽肠溶胶囊及其制备方法

Similar Documents

Publication Publication Date Title
US12257229B2 (en) Peptide pharmaceuticals for treatment of NASH and other disorders
JP5749879B2 (ja) ペプチドyyおよびペプチドyyアゴニストの送達用組成物
RU2492183C2 (ru) Пептид, фармацевтическая композиция (варианты) и лекарственное средство на его основе, способ лечения и/или предупреждения диабета или заболеваний, сопутствующих ожирению, способ уменьшения аппетита, уменьшения потребления пищи, уменьшения потребления калорий, уменьшения массы тела и увеличения расхода энергии
JP4898078B2 (ja) 薬理学的活性剤の経口的送達のための医薬組成物
US20050009748A1 (en) Compositions for delivering peptide YY and PYY agonists
JP6118107B2 (ja) Raの処置のためのカルシトニンの使用
WO2023066293A1 (en) Oral delivery of therapeutic agents
CN1809377B (zh) 包含微粉化形式的传送剂的口服给药药物组合物
ES2393324T3 (es) Compuestos y composiciones para administrar principios activos
JP2024501467A (ja) 新規化合物
CN106255701A (zh) 可从前胰高血糖素原衍生出的肽激素类似物
JP2025525218A (ja) インクレチンアナログおよびその使用
CN118019522A (zh) 包含大的生理活性物质和赋形剂的药物组合物
EP4638481A1 (en) Glp1/gip/npy2 receptor triple agonists
CN118108832A (zh) 一种长效的类似胰淀素的多肽衍生物及其制备方法和用途
JP2022536761A (ja) 新規ペプチドホルモン類縁体
JP7279061B2 (ja) グルカゴン様ペプチド
EP0462071A1 (en) Pharmaceutical resorption-improved somatostatin compositions, their preparation and use
Wang et al. Peptide and peptide-based drugs
US20220143150A1 (en) Glucagon-like peptide-1 (glp-1) agonist analog, process of preparation and uses thereof
EP4631514A1 (en) Oral polypeptide composition and use thereof
WO2024012589A1 (zh) 一种多肽组合物、药物、药物组合物及其应用
JP5264725B2 (ja) ペプチド性薬物の粘膜吸収促進剤を含有する粘膜投与用組成物、及びその投与方法
JPH069424A (ja) 経粘膜用製剤
US20260077020A1 (en) Oral peptide pharmaceutical composition that facilitates enhanced oral absorption